Abstract

Pure red cell aplasia (PRCA) is a rare hematological disorder with multiple etiologies. The multifaceted nature of this disease is emphasized by the variety of concomitant clinical features. Classic idiopathic presentation aside, prompt recognition of pathogenetic clues is important because of their diagnostic and therapeutic implications. As a consequence, treatment of PRCA is diverse and strictly dependent on the presented clinical scenario. Here, we propose a series of clinical vignettes that showcase instructive representative situations derived from our routine clinical practice. Using these illustrative clinical cases, we review the diagnostic workup needed for a precise diagnosis and the currently available therapeutic options, discussing their applications in regard to the various PRCA-associated conditions and individual patients’ characteristics. Finally, we propose a treatment algorithm that may offer guidance for personalized therapeutic recommendations.

REFERENCES

1.
Sawada
K
,
Fujishima
N
,
Hirokawa
M
.
Acquired pure red cell aplasia: updated review of treatment
.
Br J Haematol
.
2008
;
142
(
4
):
505
-
514
.
2.
Young
NS
,
Maciejewski
J
.
The pathophysiology of acquired aplastic anemia
.
N Engl J Med
.
1997
;
336
(
19
):
1365
-
1372
.
3.
Ulirsch
JC
,
Verboon
JM
,
Kazerounian
S
, et al
.
The genetic landscape of Diamond-Blackfan anemia [published correction appears in Am J Hum Genet. 2019;104(2):356]
.
Am J Hum Genet
.
2018
;
103
(
6
):
930
-
947
.
4.
Narla
A
,
Vlachos
A
,
Nathan
DG
.
Diamond Blackfan anemia treatment: past, present, and future
.
Semin Hematol
.
2011
;
48
(
2
):
117
-
123
.
5.
Frickhofen
N
,
Chen
ZJ
,
Young
NS
,
Cohen
BJ
,
Heimpel
H
,
Abkowitz
JL
.
Parvovirus B19 as a cause of acquired chronic pure red cell aplasia
.
Br J Haematol
.
1994
;
87
(
4
):
818
-
824
.
6.
Brown
KE
,
Hibbs
JR
,
Gallinella
G
, et al
.
Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen)
.
N Engl J Med
.
1994
;
330
(
17
):
1192
-
1196
.
7.
Means
RT
Jr.
Pure red cell aplasia
.
Blood
.
2016
;
128
(
21
):
2504
-
2509
.
8.
Casadevall
N
,
Nataf
J
,
Viron
B
, et al
.
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
.
N Engl J Med
.
2002
;
346
(
7
):
469
-
475
.
9.
Bennett
CL
,
Cournoyer
D
,
Carson
KR
, et al
.
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
.
Blood
.
2005
;
106
(
10
):
3343
-
3347
.
10.
Carson
KR
,
Evens
AM
,
Bennett
CL
,
Luminari
S
.
Clinical characteristics of erythropoietin-associated pure red cell aplasia
.
Best Pract Res Clin Haematol
.
2005
;
18
(
3
):
467
-
472
.
11.
Bennett
CL
,
Starko
KM
,
Thomsen
HS
, et al
.
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye’s syndrome. a report from the Southern Network on Adverse Reactions (SONAR)
.
J Gen Intern Med
.
2012
;
27
(
12
):
1697
-
1703
.
12.
Dessypris
EN
,
Redline
S
,
Harris
JW
,
Krantz
SB
.
Diphenylhydantoin-induced pure red cell aplasia
.
Blood
.
1985
;
65
(
4
):
789
-
794
.
13.
Mariette
X
,
Mitjavila
MT
,
Moulinie
JP
, et al
.
Rifampicin-induced pure red cell aplasia
.
Am J Med
.
1989
;
87
(
4
):
459
-
460
.
14.
Lacy
MQ
,
Kurtin
PJ
,
Tefferi
A
.
Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities
.
Blood
.
1996
;
87
(
7
):
3000
-
3006
.
15.
Gurnari
C
,
Durrani
J
,
Pagliuca
S
, et al
.
Novel invariant features of Good syndrome [published online ahead of print 7 January 2021]
.
Leukemia
.
doi:10.1038/s41375-020-01114-z
.
16.
Hirokawa
M
,
Sawada
K
,
Fujishima
N
, et al;
PRCA Collaborative Study Group
.
Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group
.
Haematologica
.
2008
;
93
(
1
):
27
-
33
.
17.
Balasubramanian
SK
,
Sadaps
M
,
Thota
S
, et al
.
Rational management approach to pure red cell aplasia
.
Haematologica
.
2018
;
103
(
2
):
221
-
230
.
18.
DeZern
AE
,
Pu
J
,
McDevitt
MA
,
Jones
RJ
,
Brodsky
RA
.
Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure disorders
.
Exp Hematol
.
2013
;
41
(
9
):
808
-
816
.
19.
Lacombe
C
,
Casadevall
N
,
Muller
O
,
Varet
B
.
Erythroid progenitors in adult chronic pure red cell aplasia: relationship of in vitro erythroid colonies to therapeutic response
.
Blood
.
1984
;
64
(
1
):
71
-
77
.
20.
Mangan
KF
,
Shadduck
RK
.
Successful treatment of chronic refractory pure red cell aplasia with antithymocyte globulin: correlation with in vitro erythroid culture studies
.
Am J Hematol
.
1984
;
17
(
4
):
417
-
426
.
21.
Charles
RJ
,
Sabo
KM
,
Kidd
PG
,
Abkowitz
JL
.
The pathophysiology of pure red cell aplasia: implications for therapy
.
Blood
.
1996
;
87
(
11
):
4831
-
4838
.
22.
Mangla
A
,
Hamad
H
.
Pure red cell aplasia
.
Treasure Island, FL
:
StatPearls Publishing
.
2021
.
23.
Sanikommu
SR
,
Clemente
MJ
,
Chomczynski
P
, et al
.
Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL)
.
Leuk Lymphoma
.
2018
;
59
(
2
):
416
-
422
.
24.
Clemente
MJ
,
Wlodarski
MW
,
Makishima
H
, et al
.
Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia [published correction appears in Blood. 2012;120(9):1963]
.
Blood
.
2011
;
118
(
16
):
4384
-
4393
.
25.
Hara
T
,
Mizuno
Y
,
Nagata
M
, et al
.
Human gamma delta T-cell receptor-positive cell-mediated inhibition of erythropoiesis in vitro in a patient with type I autoimmune polyglandular syndrome and pure red blood cell aplasia
.
Blood
.
1990
;
75
(
4
):
941
-
950
.
26.
Levitt
LJ
,
Reyes
GR
,
Moonka
DK
,
Bensch
K
,
Miller
RA
,
Engleman
EG
.
Human T cell leukemia virus-I-associated T-suppressor cell inhibition of erythropoiesis in a patient with pure red cell aplasia and chronic T gamma-lymphoproliferative disease
.
J Clin Invest
.
1988
;
81
(
2
):
538
-
548
.
27.
Loughran
TP
Jr.
Clonal diseases of large granular lymphocytes
.
Blood
.
1993
;
82
(
1
):
1
-
14
.
28.
Pende
D
,
Falco
M
,
Vitale
M
, et al
.
Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation
.
Front Immunol
.
2019
;
10
:
1179
.
29.
Handgretinger
R
,
Geiselhart
A
,
Moris
A
, et al
.
Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors
.
N Engl J Med
.
1999
;
340
(
4
):
278
-
284
.
30.
Nagasawa
T
,
Abe
T
,
Nakagawa
T
.
Pure red cell aplasia and hypogammaglobulinemia associated with Tr-cell chronic lymphocytic leukemia
.
Blood
.
1981
;
57
(
6
):
1025
-
1031
.
31.
Abkowitz
JL
,
Kadin
ME
,
Powell
JS
,
Adamson
JW
.
Pure red cell aplasia: lymphocyte inhibition of erythropoiesis
.
Br J Haematol
.
1986
;
63
(
1
):
59
-
67
.
32.
Fehr
J
,
Hofmann
V
,
Kappeler
U
.
Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin
.
N Engl J Med
.
1982
;
306
(
21
):
1254
-
1258
.
33.
Bernard
C
,
Frih
H
,
Pasquet
F
, et al
.
Thymoma associated with autoimmune diseases: 85 cases and literature review
.
Autoimmun Rev
.
2016
;
15
(
1
):
82
-
92
.
34.
Aung
FM
,
Lichtiger
B
,
Bassett
R
, et al
.
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation
.
Br J Haematol
.
2013
;
160
(
6
):
798
-
805
.
35.
Bolan
CD
,
Leitman
SF
,
Griffith
LM
, et al
.
Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation
.
Blood
.
2001
;
98
(
6
):
1687
-
1694
.
36.
Worel
N
.
ABO-mismatched allogeneic hematopoietic stem cell transplantation
.
Transfus Med Hemother
.
2016
;
43
(
1
):
3
-
12
.
37.
Marco-Ayala
J
,
Gómez-Seguí
I
,
Sanz
G
,
Solves
P
.
Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question [published ahead of print 14 November 2020]
.
Bone Marrow Transplant
.
doi:10.1038/s41409-020-01124-6
.
38.
Butcher
D
,
Deplano
S
,
Lofaro
T
.
Copper levels in patients with unexplained dysplastic cytopenia
.
Biol Trace Elem Res
.
2020
;
199
(
3
):
825
-
828
.
39.
Long
Z
,
Li
H
,
Du
Y
,
Chen
M
,
Zhuang
J
,
Han
B
.
Gene mutation profile in patients with acquired pure red cell aplasia
.
Ann Hematol
.
2020
;
99
(
8
):
1749
-
1754
.
40.
Zhang
X
,
Shi
Y
,
Song
L
, et al
.
Identification of mutations in patients with acquired pure red cell aplasia
.
Acta Biochim Biophys Sin (Shanghai)
.
2018
;
50
(
7
):
685
-
692
.
41.
Ishida
F
,
Matsuda
K
,
Sekiguchi
N
, et al
.
STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia
.
Cancer Sci
.
2014
;
105
(
3
):
342
-
346
.
42.
Kawakami
T
,
Sekiguchi
N
,
Kobayashi
J
, et al
.
Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia
.
Blood Adv
.
2018
;
2
(
20
):
2704
-
2712
.
43.
Koskela
HL
,
Eldfors
S
,
Ellonen
P
, et al
.
Somatic STAT3 mutations in large granular lymphocytic leukemia
.
N Engl J Med
.
2012
;
366
(
20
):
1905
-
1913
.
44.
Fu
R
,
Zhang
T
,
Liu
B
, et al
.
The clinical characteristics and therapy response of patients with acquired pure red cell aplasia
.
Hematology
.
2018
;
23
(
9
):
639
-
645
.
45.
Korde
N
,
Zhang
Y
,
Loeliger
K
, et al
.
Monoclonal gammopathy-associated pure red cell aplasia
.
Br J Haematol
.
2016
;
173
(
6
):
876
-
883
.
46.
Au
WY
,
Cheng
VC
,
Wan
TS
,
Ma
SK
.
Myelodysplasia masquerading as parvovirus-related red cell aplasia with giant pronormoblasts
.
Ann Hematol
.
2004
;
83
(
10
):
670
-
671
.
47.
Young
NS
,
Brown
KE
.
Parvovirus B19
.
N Engl J Med
.
2004
;
350
(
6
):
586
-
597
.
48.
Fargo
JH
,
Kratz
CP
,
Giri
N
, et al
.
Erythrocyte adenosine deaminase: diagnostic value for Diamond-Blackfan anaemia
.
Br J Haematol
.
2013
;
160
(
4
):
547
-
554
.
49.
Vlachos
A
,
Muir
E
.
How I treat Diamond-Blackfan anemia
.
Blood
.
2010
;
116
(
19
):
3715
-
3723
.
50.
Bartels
M
,
Bierings
M
.
How I manage children with Diamond-Blackfan anaemia
.
Br J Haematol
.
2019
;
184
(
2
):
123
-
133
.
51.
Dessypris
EN
. Pure red cell aplasia. In:
Shahidi
NT
, ed.
Aplastic Anemia and Other Bone Marrow Failure Syndromes
,
New York, NY
:
Springer New York
;
1990
:
179
-
198
.
52.
Mamiya
S
,
Itoh
T
,
Miura
AB
.
Acquired pure red cell aplasia in Japan
.
Eur J Haematol
.
1997
;
59
(
4
):
199
-
205
.
53.
Marmont
AM
.
Therapy of pure red cell aplasia
.
Semin Hematol
.
1991
;
28
(
4
):
285
-
297
.
54.
Hirokawa
M
,
Sawada
K
,
Fujishima
N
, et al;
PRCA Collaborative Study Group
.
Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group
.
Br J Haematol
.
2015
;
169
(
6
):
879
-
886
.
55.
Sawada
K
,
Hirokawa
M
,
Fujishima
N
, et al;
PRCA Collaborative Study Group
.
Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group
.
Haematologica
.
2007
;
92
(
8
):
1021
-
1028
.
56.
Tötterman
TH
,
Höglund
M
,
Bengtsson
M
,
Simonsson
B
,
Almqvist
D
,
Killander
A
.
Treatment of pure red-cell aplasia and aplastic anaemia with ciclosporin: long-term clinical effects
.
Eur J Haematol
.
1989
;
42
(
2
):
126
-
133
.
57.
Young
NS
,
Calado
RT
,
Scheinberg
P
.
Current concepts in the pathophysiology and treatment of aplastic anemia
.
Blood
.
2006
;
108
(
8
):
2509
-
2519
.
58.
Yoshida
S
,
Konishi
T
,
Nishizawa
T
,
Yoshida
Y
.
Effect of tacrolimus in a patient with pure red-cell aplasia
.
Clin Lab Haematol
.
2005
;
27
(
1
):
67
-
69
.
59.
Patil
MR
,
Choudhury
AR
,
Chohwanglim
M
,
Divyaveer
S
,
Mahajan
C
,
Pandey
R
.
Post renal transplant pure red cell aplasia-is tacrolimus a culprit?
Clin Kidney J
.
2016
;
9
(
4
):
603
-
605
.
60.
Reinhold-Keller
E
,
Beuge
N
,
Latza
U
, et al
.
An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients
.
Arthritis Rheum
.
2000
;
43
(
5
):
1021
-
1032
.
61.
Talar-Williams
C
,
Hijazi
YM
,
Walther
MM
, et al
.
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis
.
Ann Intern Med
.
1996
;
124
(
5
):
477
-
484
.
62.
Yamada
O
,
Mizoguchi
H
,
Oshimi
K
.
Cyclophosphamide therapy for pure red cell aplasia associated with granular lymphocyte-proliferative disorders
.
Br J Haematol
.
1997
;
97
(
2
):
392
-
399
.
63.
Go
RS
,
Li
CY
,
Tefferi
A
,
Phyliky
RL
.
Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes
.
Blood
.
2001
;
98
(
2
):
483
-
485
.
64.
Zeok
JV
,
Todd
EP
,
Dillon
M
,
DeSimone
P
,
Utley
JR
.
The role of thymectomy in red cell aplasia
.
Ann Thorac Surg
.
1979
;
28
(
3
):
257
-
260
.
65.
Thompson
CA
,
Steensma
DP
.
Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience
.
Br J Haematol
.
2006
;
135
(
3
):
405
-
407
.
66.
Hoffacker
V
,
Schultz
A
,
Tiesinga
JJ
, et al
.
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease
.
Blood
.
2000
;
96
(
12
):
3872
-
3879
.
67.
Gerli
R
,
Paganelli
R
,
Cossarizza
A
, et al
.
Long-term immunologic effects of thymectomy in patients with myasthenia gravis
.
J Allergy Clin Immunol
.
1999
;
103
(
5
):
865
-
872
.
68.
Wolfe
GI
,
Kaminski
HJ
,
Aban
IB
, et al;
MGTX Study Group
.
Randomized trial of thymectomy in myasthenia gravis [published correction appears in N Engl J Med. 2017;376(21):2097]
.
N Engl J Med
.
2016
;
375
(
6
):
511
-
522
.
69.
Yancy
CW
,
Jessup
M
,
Bozkurt
B
, et al
.
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
.
Circulation
.
2017
;
136
(
6
):
e137
-
e161
.
70.
Schützinger
C
,
Gaiger
A
,
Thalhammer
R
, et al
.
Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab
.
Leukemia
.
2005
;
19
(
11
):
2005
-
2008
.
71.
Hale
G
.
The CD52 antigen and development of the CAMPATH antibodies
.
Cytotherapy
.
2001
;
3
(
3
):
137
-
143
.
72.
Willis
F
,
Marsh
JC
,
Bevan
DH
, et al
.
The effect of treatment with Campath-1H in patients with autoimmune cytopenias
.
Br J Haematol
.
2001
;
114
(
4
):
891
-
898
.
73.
Ru
X
,
Liebman
HA
.
Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H)
.
Br J Haematol
.
2003
;
123
(
2
):
278
-
281
.
74.
Au
WY
,
Lam
CC
,
Chim
CS
,
Pang
AW
,
Kwong
YL
.
Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia
.
Leuk Res
.
2005
;
29
(
10
):
1213
-
1215
.
75.
Dumitriu
B
,
Ito
S
,
Feng
X
, et al
.
Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study
.
Lancet Haematol
.
2016
;
3
(
1
):
e22
-
e29
.
76.
Risitano
AM
,
Selleri
C
,
Serio
B
, et al;
Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT)
.
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA
.
Br J Haematol
.
2010
;
148
(
5
):
791
-
796
.
77.
Thota
S
,
Patel
BJ
,
Sadaps
M
, et al
.
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions
.
Br J Haematol
.
2018
;
183
(
1
):
133
-
136
.
78.
Tuset
E
,
Matutes
E
,
Brito-Babapulle
V
,
Morilla
R
,
Catovsky
D
.
Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia
.
Leuk Lymphoma
.
2001
;
42
(
6
):
1379
-
1383
.
79.
Mohan
SR
,
Clemente
MJ
,
Afable
M
, et al
.
Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia
.
Haematologica
.
2009
;
94
(
10
):
1407
-
1414
.
80.
Hattori
M
,
Terasawa
T
,
Tsushita
K
, et al
.
The status of antithymocyte globulin therapy for adult patients in Japan: retrospective analysis of a nationwide survey
.
Int J Hematol
.
2008
;
87
(
1
):
48
-
55
.
81.
Abkowitz
JL
,
Powell
JS
,
Nakamura
JM
,
Kadin
ME
,
Adamson
JW
.
Pure red cell aplasia: response to therapy with anti-thymocyte globulin
.
Am J Hematol
.
1986
;
23
(
4
):
363
-
371
.
82.
Long
Z
,
Yu
F
,
Du
Y
, et al
.
Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus
.
Ann Hematol
.
2018
;
97
(
11
):
2047
-
2054
.
83.
Chen
Z
,
Liu
X
,
Chen
M
,
Yang
C
,
Han
B
.
Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency
.
Ann Hematol
.
2020
;
99
(
4
):
737
-
741
.
84.
Kurtzman
G
,
Frickhofen
N
,
Kimball
J
,
Jenkins
DW
,
Nienhuis
AW
,
Young
NS
.
Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy
.
N Engl J Med
.
1989
;
321
(
8
):
519
-
523
.
85.
Dungarwalla
M
,
Marsh
JC
,
Tooze
JA
, et al
.
Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology
.
Ann Hematol
.
2007
;
86
(
3
):
191
-
197
.
86.
Zecca
M
,
De Stefano
P
,
Nobili
B
,
Locatelli
F
.
Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia
.
Blood
.
2001
;
97
(
12
):
3995
-
3997
.
87.
Halkes
C
,
de Wreede
LC
,
Knol
C
, et al;
European Society for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party
.
Allogeneic stem cell transplantation for acquired pure red cell aplasia
.
Am J Hematol
.
2019
;
94
(
11
):
E294
-
E296
.
88.
Tseng
SB
,
Lin
SF
,
Chang
CS
, et al
.
Successful treatment of acquired pure red cell aplasia (PRCA) by allogeneic peripheral blood stem cell transplantation
.
Am J Hematol
.
2003
;
74
(
4
):
273
-
275
.
You do not currently have access to this content.

Sign in via your Institution

Sign In